Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT00152451
Ignite Creation Date: 2024-05-05 @ 11:52 AM
Last Modification Date: 2024-10-26 @ 9:14 AM
Study NCT ID: NCT00152451
Protocol Section: NCT00152451
Start Identification Module Data
Expand Identification Module Data
Brief Title: Study With Seletracetam Ucb 44212 in Adult Subjects 18 to 65 Years With Partial Onset Seizures
Official Title: An Open-label Exploratory Multicenter Dose-escalation Study Examining the Efficacy Safety and Tolerability of Ucb 44212 Used at Doses of 10 mg 20 mg 40 mg and 80 mg bid Total Daily Dose of 20 to 160 mg in Adult Subjects 18-65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized and Treated With 1 2 or 3 Approved Antiepileptic Drugs
Acronym: None
Organization: UCB Pharma
Organization Class: INDUSTRY
Organization Study ID: N01191
Start Status Module Data
Status Verified Date: 2023-09
Overall Status: COMPLETED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: UCB SA - Pharma Sector
Lead Sponsor Class: INDUSTRY
Lead Sponsor: UCB SA - Pharma Sector
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload